<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314934</url>
  </required_header>
  <id_info>
    <org_study_id>ANAVEX2-73-AD-EP-004</org_study_id>
    <nct_id>NCT04314934</nct_id>
  </id_info>
  <brief_title>OLE for Patients Enrolled in Phase 2b/3 Study ANAVEX2-73-AD-004</brief_title>
  <acronym>ATTENTION-AD</acronym>
  <official_title>Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anavex Life Sciences Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anavex Australia Pty Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anavex Germany GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anavex Life Sciences Corp.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on
      safety and effficacy of daily treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on
      safety and effficacy of daily treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>96 weeks</time_frame>
    <description>To continue assessing the safety and tolerability of ANAVEX2-73</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change from baseline to week 96 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADCS-ADL (Activities of Daily Living)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change from baseline to week 96 in ability to perform daily activities according to the Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANAVEX2-73</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANAVEX2-73</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Blarcamesine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous completion of participation in the ANAVEX2-73-AD-004 double-blind study.

          -  Participants may be either outpatients, or residents of an assisted-living facility.

          -  Participants must have a designated study partner, who spends at least 10hrs per week
             with the participant, in order that assessments e.g. carer burden instruments are
             completed with true knowledge of the participant.

          -  No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale
             (C-SSRS) in the past 3 months (i.e. active suicidal thought(s) with intent but without
             specific plan, or active suicidal thought(s) with plan and intent) OR suicidal
             behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted
             attempt, or preparatory acts or behavior).

          -  Confirmation from the participant that, if of childbearing potential is not pregnant
             through urine pregnancy testing.

        Exclusion Criteria:

          -  Adverse events (AEs) from the previous study (ANAVEX2-73-AD-004) that have not
             resolved, are moderate or severe, judged to be possibly related or related to study
             drug, and considered by the investigator to be a contraindication to extension study
             participation

          -  Any condition or laboratory abnormality that would make the subject, in the judgment
             of the investigator, unsuitable for the study

          -  Significant history of drug addiction (with the exception of nicotine dependence) or
             abuse (including alcohol, as defined in DSM-V or in the opinion of the investigator)
             within the last two years prior to informed consent, or a positive urine drug screen
             for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at screening.
             Prescription medication yielding a positive drug screen are acceptable except for
             tricyclic antidepressants (e.g. Amitriptyline, Amoxapine, Desipramine, (Norpramin)
             Doxepin, Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil),
             Trimipramine (Surmontil)).

          -  Any known hypersensitivity to any of the excipients contained in the study drug
             formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>844-689-3939</phone>
    <email>alz@anavex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sydney</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney</name>
      <address>
        <city>Sydney</city>
        <state>NEW</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gold Coast</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adelaide</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne</name>
      <address>
        <city>Belmont</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne</name>
      <address>
        <city>Melbourne N.</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne</name>
      <address>
        <city>Delmont</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne</name>
      <address>
        <city>Melbourne E.</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

